重组甲硫氨酸酶（rMETase）在难治性癌症患者来源的原位异种移植（PDOX）小鼠模型中的疗效：综述。

AntiCancer, Inc., San Diego, CA 92111, USA.

Department of Surgery, University of California, San Diego, CA 92093, USA.

Cells. 2019 May 2;8(5):410. doi: 10.3390/cells8050410.

An excessive requirement for methionine (MET), termed MET dependence, appears to be a general metabolic defect in cancer and has been shown to be a very effective therapeutic target. MET restriction (MR) has inhibited the growth of all major cancer types by selectively arresting cancer cells in the late-S/G phase, when they also become highly sensitive to cytotoxic agents. Recombinant methioninase (rMETase) has been developed to effect MR. The present review describes the efficacy of rMETase on patient-derived orthotopic xenograft (PDOX) models of recalcitrant cancer, including the surprising result that rMETase administrated orally can be highly effective.

对蛋氨酸（MET）的过度需求，称为 MET 依赖性，似乎是癌症中的一种普遍代谢缺陷，并且已被证明是一种非常有效的治疗靶点。MET 限制（MR）通过选择性地将癌细胞阻滞在晚期 S/G 期来抑制所有主要癌症类型的生长，此时癌细胞对细胞毒性药物也变得高度敏感。已经开发出重组蛋氨酸酶（rMETase）来实现 MR。本综述描述了 rMETase 在难治性癌症的患者来源的原位异种移植（PDOX）模型中的疗效，包括令人惊讶的结果，即口服给予 rMETase 可以非常有效。